Femasys Inc Ordinary Shares FEMY 深 滬
已收盤 10-03 16:00:00 美东时间
0.6301
+0.215
+51.87%
華盛通- 最 高0.6475
- 今 開0.44
- 成交量 2631.03万股
- 最 低 0.4139
- 昨 收 0.4149
- 總市值 2772.69万
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 59.79%
- 52周最低 0.3067
- 委 比 29.63%
- 總股本 4400.40万
- 歷史最高 13.75
- 量 比 27.61
- 振 幅 56.30%
- 歷史最低 0.2479
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
<p>Femasys Inc. has partnered with Kebomed to commercialize its FemBloc permanent birth control in France and the Benelux region, leveraging Kebomed’s extensive European distribution network. FemBloc, a first-of-its-kind non-surgical solution for permanent contraception, addresses unmet needs in women’s reproductive health by eliminating risks associated with surgical sterilization. This collaboration marks a significant step in Femasys’ European...
09-25 13:00
Femasys Partners With Medical Electronic Systems To Provide Advanced Sperm Analysis Technology
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Medical
09-22 21:02
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
Femasys Inc. partners with Medical Electronic Systems LLC (MES) to offer advanced sperm analysis technology, completing the FemSperm product family. This enables gynecologists to perform in-office sperm preparation and analysis for FemaSeed Intratubal Insemination, a cost-effective infertility treatment. The collaboration enhances Femasys’ infertility portfolio and expands access to quality care.
09-22 13:00
Femasys Launches FemSperm Insemination Prep Kit To Boost Gynecologist Adoption Of FemaSeed Fertility Treatment
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its FemSperm
09-11 21:05
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
Femasys Inc.推出FemSperm Insemination Prep Kit，支持妇科医生执行FemaSeed Intratubal Insemination。该产品优化精子处理，方便诊所内治疗，提高生育服务可及性。FemaSeed已获多国授权，低精子情况下的怀孕率高于传统IUI，成本低、风险低，助力公司增长。
09-11 13:00
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
Femasys Inc. secures $8 million in financing to accelerate commercialization of its women's health products, including FemSeed® and FemBloc®, which address unmet needs in infertility and non-surgical contraception. Recent milestones include regulatory approvals for FemBloc in Europe and the UK, commercial entry into Spain, and partnerships with leading healthcare institutions. CEO Jorey Chernett highlights the importance of these innovations, emp...
09-02 13:00
生物技术公司Femasys重挫35.7%，此前宣布将公开发行募集800万美元资金
美股周二早盘，生物技术公司Femasys（FEMY）股价重挫35.7%，此前该公司宣布通过公开发行募集800万美元资金，所筹资金将用于支持该公司的商业扩张和...
08-26 23:09
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Invivyd (NASDAQ:IVVD) stock increased by 132.3% to $1.3 during Tuesday...
08-26 20:09
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
Femasys Inc. has launched the FemSperm Setup Kit, the first product in its FemSperm family, designed to enable gynecologists to offer FemaSeed Intratubal Insemination as a first-step fertility treatment. The kit simplifies sperm preparation in-office, expanding patient access to alternatives before IVF and supporting the company's commercialization strategy. FemaSeed, with proven higher pregnancy rates compared to IUI, is authorized in multiple r...
08-21 13:00
